Latest Acrux (ASX:ACR) News

Acrux Limited has secured a further $0.46 million advance on its FY25 R&D Tax Incentive, bringing total advances to $2.19 million and supporting its pharmaceutical product development and working capital needs.

Acrux Limited, partnering with TruPharma, has introduced its Dapsone 7.5% Gel in the US, featuring a unique tube packaging that aims to improve patient convenience and reduce environmental impact.

Acrux Limited has appointed John Warmbrunn as its new CEO and Managing Director, signaling a strategic push for international expansion and product development starting June 2025.

Acrux Limited reports strong momentum from recent topical pharmaceutical launches, driving a significant uptick in profit share income expected in the coming quarter. The company also secured nearly $4 million through a placement and share purchase plan, alongside a $1.73 million R&D-backed loan.

Acrux Limited announces the retirement of CEO Michael Kotsanis after more than 10 years at the helm, with a search underway for his successor to lead the next phase of growth.

Acrux Limited has launched its Nitroglycerin 0.4% Ointment and successfully raised nearly $4 million, positioning the specialty pharma company for sustained revenue growth.